Bad Patents, Thwarted Patent Reform, and a Failure to AdaptScott McKeown discusses the complexities and challenges facing the PTAB, including the role of patent reform and the impact of extreme views in policymaking.
PREVAIL Act Narrowly Moves Forward Despite Concerns About Drug Pricing ImpactThe PREVAIL Act is contentious, particularly regarding its potential impact on drug pricing and challenges to pharmaceutical patents.
USPTO Tweaks PTAB AIA-Trial Counsel Rules; NO Major OverhaulUSPTO final rules expand opportunities for PTAB representation, effective November 12, 2024.Lead counsel in AIA-trial proceedings must be a registered patent practitioner.
A Look at Key USPTO Director Review Decisions and their SignificanceThe landscape of Director Review (DR) decisions in 2024 is shifting towards party-initiated DRs over sua-sponte focused DRs.
USPTO Tweaks PTAB AIA-Trial Counsel Rules; NO Major OverhaulUSPTO final rules expand opportunities for PTAB representation, effective November 12, 2024.Lead counsel in AIA-trial proceedings must be a registered patent practitioner.
A Look at Key USPTO Director Review Decisions and their SignificanceThe landscape of Director Review (DR) decisions in 2024 is shifting towards party-initiated DRs over sua-sponte focused DRs.